DHF patients present decreased plasma levels of fibrinogen and plasminogen, reduced α2-antiplasmin activity and an increase of fibrin degradation products, plasmin-antiplasmin complexes and tissue-type plasminogen activator (tPA), indicating that patients with life-threatening forms of dengue develop hyperfibrinolysis [5]–[14]. The gene discussed is PLG; the disease is Dengue hemorrhagic fever.